Dynavax Technologies Corp

Health Care
Biotechnology: Pharmaceutical Preparations
www.dynavax.com

Earnings Score
Moat Score

Market Cap $1.37B
PE 50
Debt -
Cash $96.15M
EV -
FCF $60.16M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$27.31M
EBIT	$30.86M
ROE	5%
ROA	3%
FCF	$60.16M
Equity	$596.80M
Growth Stability	-7%
PE	50.21
PEG	-1.14
PB	2.3
P/FCF	22.79
P/S	4.95
Price/Cash	0.07
Net Margins	10%
Gross Margins	82%
Op. Margins	11%
Earnings CAGR	-3%
Sales Growth YoY	30%
Sales Growth QoQ	-11%
Sales CAGR	107%
FCF CAGR	-3%
Equity CAGR	22%
Earnings Stability	0.02
Earnings Growth YoY	3K%

Earnings Growth QoQ	-60%
Earnings CAGR 5Y	-44%
Sales CAGR 5Y	53%
FCF CAGR 5Y	-37%
Equity CAGR 5Y	106%
Earnings CAGR 3Y	-35%
Sales CAGR 3Y	-35%
FCF CAGR 3Y	-45%
Equity CAGR 3Y	23%
Market Cap	$1.37B
Revenue	$277.25M
Assets	$986.26M
Cash	$96.15M
Shares Outstanding	125.45M
Earnings Score	6%
Moat Score	58%
Working Capital	770.31M
Current Ratio	10.8
Gross Profit	$227.80M
Shares Growth 3y	1%
Equity Growth QoQ	-12%
Equity Growth YoY	-4%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product.

SEC Filings

Direct access to Dynavax Technologies Corp (DVAX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Dynavax Technologies Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Dynavax Technologies Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -3%

Stability 2%

loading chart...

Dynavax Technologies Corp Discounted Cash Flow

Fully customizable DCF calculator online for Dynavax Technologies Corp.

Years

Calculation mode

= $483M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$60M	$58M	$56M	$54M	$53M	$51M	$49M	$48M	$46M	$44M	$43M	$430M
DCF		$53M	$46M	$41M	$36M	$32M	$28M	$24M	$21M	$19M	$17M	$166M
Value	$483M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-3K%	-1K%	-29K%	-2K%	-443%	-162%	16%	41%	-3%	10%	10%
ROA	-	-101%	-44%	-71%	-48%	-19%	13%	30%	-0%	3%	3%
ROE	-	-126%	-48%	-252%	-2K%	-128%	32%	50%	-1%	5%	5%

Net Margins (9.85%)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-0.74	-1.24	-1.87	0	-	-	-	-
Debt over Equity	-	-	-	1.6	21.54	3.06	0	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	-7%	23%	-7%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (-7%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	173%	-97%	2K%	330%	32%	844%	64%	-68%	19%	53%
Earnings YoY growth	-	5%	-15%	67%	-2%	-52%	-196%	306%	-102%	-527%	-44%
Equity YoY growth	-	-52%	124%	-68%	-87%	608%	279%	161%	7%	-4%	106%
FCF YoY growth	-	15%	-32%	73%	6%	-33%	-438%	-83%	74%	-38%	-37%